Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
CARTIA XT vs ADALAT CC
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Diltiazem, a benzothiazepine calcium channel blocker, inhibits calcium ion influx across cardiac and vascular smooth muscle cells during depolarization, leading to vasodilation and reduced myocardial contractility and conduction velocity, particularly at the AV node.
Nifedipine, a dihydropyridine calcium channel blocker, inhibits calcium ion influx across cardiac and smooth muscle cell membranes, leading to vasodilation and decreased myocardial contractility.
FDA-approved: hypertension,FDA-approved: chronic stable angina,FDA-approved: atrial fibrillation or flutter (rate control),Off-label: prevention of migraine,Off-label: anal fissure (topical)
Hypertension,Chronic stable angina,Vasospastic angina (Prinzmetal's angina)
Diltiazem hydrochloride extended-release capsules (CARTIA XT) are administered orally. For hypertension and angina, the typical adult dose is 180–360 mg once daily, initially 180 mg once daily, titrated to response.
30 mg orally once daily; may titrate to 60 mg or 90 mg once daily based on response and tolerability.
Terminal half-life 3-4.5 hours; prolonged in hepatic impairment (up to 15 hours) or with cimetidine.
Terminal elimination half-life: 7-10 hours; clinical context: sustained-release formulation provides therapeutic concentrations over 24 hours with once-daily dosing, but half-life does not directly reflect drug effect duration due to slow absorption.
Primarily hepatic via CYP3A4; extensive first-pass metabolism. Metabolites include desacetyldiltiazem (active, 25-50% potency).
Hepatic metabolism via CYP3A4; nifedipine is converted to inactive metabolites.
Renal (biliary/fecal minimal). 70-80% excreted as inactive metabolites in urine; 15% unchanged.
Renal: 70-80% as metabolites, fecal: 15-20% as metabolites, biliary: minimal (<5% unchanged).
40-50% bound to albumin.
92-98% bound primarily to albumin.
Vd 5-10 L/kg; reflects extensive tissue distribution (highly lipophilic).
1.2-1.6 L/kg; clinical meaning: indicates extensive tissue distribution, with higher concentrations in organs such as liver and kidney, and lower in brain due to P-glycoprotein efflux.
IR: 30-40% (first-pass metabolism); ER (CARTIA XT): 30-40% relative to IR.
65-90% after oral administration; absolute bioavailability of nifedipine in ADALAT CC: approximately 65% due to first-pass metabolism in liver and gut wall.
No specific dose adjustment is required for renal impairment. However, use with caution in patients with severe renal impairment (Cr Cl <30 m L/min) and monitor heart rate and blood pressure.
No dose adjustment required for mild to moderate renal impairment. For severe renal impairment (Cr Cl <30 m L/min), start at 30 mg once daily and titrate cautiously.
Contraindicated in acute hepatic injury. For mild to moderate hepatic impairment (Child-Pugh class A/B), reduce starting dose by 50% and titrate slowly. For severe hepatic impairment (Child-Pugh class C), use is not recommended.
For mild to moderate hepatic impairment (Child-Pugh A or B), reduce initial dose to 30 mg once daily; for severe impairment (Child-Pugh C), contraindicated or use with extreme caution.
Safety and efficacy in pediatric patients have not been established. No standard weight-based dosing guidelines are available.
Safety and efficacy not established; use is not recommended in pediatric patients.
In elderly patients (≥65 years), start at the lower end of the dosing range (e.g., 120–180 mg once daily) due to increased potential for bradycardia and hypotension; titrate cautiously.
Initiate at 30 mg once daily; titrate slowly due to increased risk of hypotension and higher drug exposure. Monitor closely.
None
No FDA black box warning.
Heart failure: may worsen systolic function due to negative inotropic effects,Sick sinus syndrome or AV block: risk of bradycardia, heart block,Concomitant beta-blocker use: increased risk of bradycardia, heart failure,Hepatic impairment: reduce dose,Renal impairment: use caution,Abrupt discontinuation: may cause angina exacerbation,Sinus bradycardia: monitor heart rate
Beta-blocker withdrawal: taper if discontinuing; exacerbation of angina,Heart failure: use caution in patients with severe left ventricular dysfunction,Hepatic impairment: reduce dose,Peripheral edema: may occur; differentiate from worsening heart failure,Monitor blood pressure during initiation and titration
Hypersensitivity to diltiazem or any component,Sick sinus syndrome (except with functioning pacemaker),Second- or third-degree AV block (except with pacemaker),Left ventricular systolic dysfunction (ejection fraction <40%) with pulmonary congestion,Severe hypotension (systolic BP <90 mm Hg),Concurrent use of ivabradine
Hypersensitivity to nifedipine or any component,Cardiogenic shock,Concurrent use with strong CYP3A4 inducers (e.g., rifampin)
Avoid grapefruit and grapefruit juice as they can increase diltiazem levels and risk of side effects. Avoid high-fat meals close to dosing as they may affect absorption. Limit alcohol intake as it may worsen hypotension or dizziness.
Avoid grapefruit and grapefruit juice as they inhibit CYP3A4 metabolism, raising nifedipine levels and risk of toxicity. High-fat meals may increase absorption; take consistently with respect to meals. Avoid alcohol as it may exacerbate hypotension.
FDA Pregnancy Category C. First trimester: No adequate studies; potential for embryotoxicity. Second and third trimesters: May cause fetal bradycardia, hypotension, hypoglycemia; risk of intrauterine growth restriction. Use only if benefit outweighs risk.
Adalat CC (nifedipine) is an extended-release formulation of nifedipine, a dihydropyridine calcium channel blocker. In animal studies, nifedipine has been associated with embryotoxicity, fetotoxicity, and teratogenicity (e.g., digital anomalies, cleft palate) at doses several times the maximum recommended human dose. In humans, data are limited but there is no clear evidence of a significant increase in major congenital malformations. First trimester exposure is not strongly associated with major defects; however, some studies suggest a possible small increase in oral clefts. Second and third trimester use may cause maternal hypotension and subsequent fetal distress (e.g., reduced uteroplacental perfusion). Use near term may theoretically inhibit labor, but nifedipine is used as a tocolytic for preterm labor. Overall, the risk is considered low; however, fetal monitoring is recommended if used in pregnancy. FDA Pregnancy Category C (prior to 2015 categorization).
Diltiazem is excreted in breast milk with a milk-to-plasma ratio of approximately 0.5-1.0. Limited data suggest low risk to infant, but consider monitoring for bradycardia and hypotension. Use with caution.
Nifedipine is excreted into human breast milk in small amounts. The milk-to-plasma (M/P) ratio is approximately 0.56 to 1.0 based on limited data. The estimated daily infant dose via milk is less than 5% of the maternal weight-adjusted dose, which is considered clinically insignificant. No adverse effects have been reported in breastfed infants. However, caution is advised, especially with high maternal doses or prolonged use. The American Academy of Pediatrics considers nifedipine compatible with breastfeeding.
No specific dose adjustments recommended; increased clearance in pregnancy may require dose titration based on clinical response. Monitor for hypotension and bradycardia. Use lowest effective dose.
Pregnancy may alter the pharmacokinetics of nifedipine due to increased plasma volume and altered hepatic metabolism. However, specific dosing adjustments for Adalat CC in pregnancy are not well established. In clinical practice, dosing for hypertension in pregnancy (e.g., preeclampsia) often uses immediate-release nifedipine, not extended-release. For Adalat CC, the same dosing as in non-pregnant adults (30-90 mg once daily) is typically used, but titration should be cautious to avoid maternal hypotension. No formal dose adjustment is recommended, but careful monitoring and individualized titration are advised.
CARTIA XT is a sustained-release formulation of diltiazem, a calcium channel blocker. Avoid use in patients with sick sinus syndrome or second/third-degree AV block without a pacemaker. Titrate slowly to prevent hypotension. Monitor heart rate and blood pressure regularly. Use with caution in hepatic or renal impairment. Can be used for rate control in atrial fibrillation but not for conversion. Swallow capsules whole; do not crush or chew.
Adalat CC (nifedipine extended-release) is a dihydropyridine calcium channel blocker used primarily for hypertension. Avoid in patients with unstable angina or within 4 weeks of myocardial infarction due to reflex tachycardia risk. May cause peripheral edema, especially in higher doses; consider adding an ACE inhibitor if edema is problematic. CYP3A4 inhibitors (e.g., grapefruit juice, macrolides, azole antifungals) significantly increase nifedipine levels; avoid coadministration. Tablet shell may appear intact in stool; this is normal.
Take this medication exactly as prescribed, usually once daily. Swallow the capsule whole; do not crush, chew, or open it.,Do not stop taking this medication suddenly without consulting your doctor, as it may worsen your condition.,Avoid drinking grapefruit juice or eating grapefruit while taking this medication.,Inform your doctor if you experience dizziness, lightheadedness, slow heartbeat, swelling of ankles/feet, or shortness of breath.,This medication may cause dizziness or drowsiness; avoid driving or operating machinery until you know how it affects you.,Keep a regular schedule for taking this medication to maintain consistent levels in your blood.
Swallow the tablet whole; do not crush or chew.,Do not consume grapefruit or grapefruit juice while taking this medication.,May cause dizziness or lightheadedness; avoid driving if affected.,Notify your doctor if you experience rapid heartbeat, swelling in the ankles or feet, or prolonged erections.,Take exactly as prescribed; do not skip doses or stop abruptly without consulting your doctor.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about CARTIA XT vs ADALAT CC, answered by our medical review team.
CARTIA XT is a Calcium Channel Blocker that works by Diltiazem, a benzothiazepine calcium channel blocker, inhibits calcium ion influx across cardiac and vascular smooth muscle cells during depolarization, leading to vasodilation and reduced myocardial contractility and conduction velocity, particularly at the AV node.. ADALAT CC is a Calcium Channel Blocker that works by Nifedipine, a dihydropyridine calcium channel blocker, inhibits calcium ion influx across cardiac and smooth muscle cell membranes, leading to vasodilation and decreased myocardial contractility.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between CARTIA XT and ADALAT CC depend on the specific clinical indication. These are both Calcium Channel Blocker agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of CARTIA XT is: Diltiazem hydrochloride extended-release capsules (CARTIA XT) are administered orally. For hypertension and angina, the typical adult dose is 180–360 mg once daily, initially 180 mg once daily, titrated to response.. The standard adult dose of ADALAT CC is: 30 mg orally once daily; may titrate to 60 mg or 90 mg once daily based on response and tolerability.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between CARTIA XT and ADALAT CC in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. CARTIA XT is classified as Category C. FDA Pregnancy Category C. First trimester: No adequate studies; potential for embryotoxicity. Second and third trimesters: May cause fetal bradycardia, hypotension, hypoglycemia; r. ADALAT CC is classified as Category C. Adalat CC (nifedipine) is an extended-release formulation of nifedipine, a dihydropyridine calcium channel blocker. In animal studies, nifedipine has been associated with embryotox. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.